ISSN: 1734-1922
Archives of Medical Science Special Issues
Current issue Archive Archives of Medical Science
1/2010
 
Share:
Share:
more
 
 
abstract:

Symptomatic treatment after ACS
Anti-anginal therapy in patients after acute coronary syndrome: evaluation of newer agents

Christian T. Ruff
,
Benjamin M. Scirica
,
David A. Morrow

Arch Med Sci 2010; 6, 1A: S 83–S 88
Online publish date: 2010/01/26
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Coronary heart disease (CAD) is the leading cause of death worldwide. Many patients who survive an acute myocardial infarction will experience recurrent angina which significantly impairs quality of life and in severe cases is associated with increased mortality. Angina occurs when there is a mismatch between coronary supply and demand. Traditional agents including b-blockers, calcium-channel blockers and nitrates exert their effect by reducing the hemodynamic components of myocardial oxygen demand such as heart rate, blood pressure and preload. After several decades without new therapies in our pharmacologic armamentarium, several promising new agents have undergone clinical evaluation with promising results. Some of these novel agents exert their anti-anginal effects through reduction in traditional hemodynamic parameters but others target novel steps in the ischemic pathway. This review examines the pharmacologic management of angina in patients after acute coronary syndrome (ACS) with a focus on novel agents.
keywords:

acute coronary syndrome, angina, nicorandil, ranolazine, trimetazidine

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe